Analysis Altimmune’s 2026 Strategy: Clinical Milestones and Financial Runway
As Altimmune moves beyond its 2025 fiscal year, the biopharmaceutical firm is squarely focused on a series of pivotal clinical developments scheduled for the near future. Bolstered by a recent...